Document Detail

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
MedLine Citation:
PMID:  19995389     Owner:  NLM     Status:  MEDLINE    
An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.
Antonio Maria Risitano; Carmine Selleri; Bianca Serio; Giovanni Fernando Torelli; Alexander Kulagin; Sébastien Maury; Jörg Halter; Vikas Gupta; Andrea Bacigalupo; Gerard Sociè; André Tichelli; Hubert Schrezenmeier; Judith Marsh; Jakob Passweg; Bruno Rotoli;
Related Documents :
24622279 - An isolate of the nematophagous fungus monacrosporium thaumasium for the control of cat...
11159509 - Long-term use of anagrelide in young patients with essential thrombocythemia.
24048759 - Ultrasonically activated shears versus electrocautery in open gastrectomy for gastric c...
7947249 - Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases.
15937689 - Cerebrospinal fluid leakage complicating skull base fractures: analysis of 81 cases.
9544169 - Pregnancy during therapy for childhood acute lymphoblastic leukemia: two case reports a...
21054679 - Innovator and generic cisplatin formulations: comparison of renal toxicity.
22290049 - Factors affecting the number of debridements in fournier’s gangrene: our results in 36...
18796519 - Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocort...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article     Date:  2009-12-07
Journal Detail:
Title:  British journal of haematology     Volume:  148     ISSN:  1365-2141     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-05-04     Completed Date:  2010-06-29     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  791-6     Citation Subset:  IM    
Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy. <>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anemia, Aplastic / drug therapy*
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects,  therapeutic use*
Cyclosporine / therapeutic use
Drug Therapy, Combination
Immunosuppressive Agents / adverse effects,  therapeutic use*
Injections, Subcutaneous
Middle Aged
Pilot Projects
Prospective Studies
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Immunosuppressive Agents; 3A189DH42V/alemtuzumab; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Modelling parasite dissemination: Host cell subversion and immune evasion by Toxoplasma gondii.
Next Document:  (188)Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell...